Appili Therapeutics Inc.
Appili Therapeutics Inc.
- Market cap
- $1.70M
Your view on APLIF
Overview
What the company does, where it operates, and who runs it.
About Appili Therapeutics Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Donald D. Cilla Jr. Pharmd
- Headquarters
- #21-1344 Summer Street, Halifax, NS, CA
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Donald D. Cilla Jr. Pharmd
- Headquarters
- #21-1344 Summer Street, Halifax, NS, CA
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada.
Its anti-infective portfolio includes Favipiravir for pandemic influenza and COVID-19; ATI-2307, an antifungal candidate, which is in clinical stage for the treatment of cryptococcal meningitis and invasive candidiasis; ATI-1503 that develops a class of gram-negative targeting antibiotics; ATI-1501, a taste-masked liquid oral suspension formulation of an antibiotic, metronidazole; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis.
The company has a strategic alliance with AiPharma Global Holdings LLC for the development of Avigan/Reeqonus (favipiravir). Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifax, Canada.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Appili Therapeutics Inc.. Starting points for Appili Therapeutics Inc.: EPS -$0.04, beta 0.07 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Appili Therapeutics Inc.. Appili Therapeutics Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Appili Therapeutics Inc.. Trailing twelve-month EPS for Appili Therapeutics Inc. stands at -$0.04. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Earnings per share estimates
| Per share | This quarterDec 2019 | Next quarterDec 2020 |
|---|---|---|
| Average estimate | −CAD 0.04 | −CAD 0.07 |
| Lowest estimate | −CAD 0.04 | −CAD 0.07 |
| Highest estimate | −CAD 0.04 | −CAD 0.07 |
| Number of analysts | 1 | 1 |
| A year ago | — | — |
| Growth vs a year ago | — | — |
Revenue estimates
| Total | This quarterDec 2019 | Next quarterDec 2020 |
|---|---|---|
| Average estimate | CAD 101132.00 | CAD 15033.00 |
| Lowest estimate | CAD 101132.00 | CAD 15033.00 |
| Highest estimate | CAD 101132.00 | CAD 15033.00 |
| Number of analysts | 1 | 1 |
| A year ago | — | — |
| Growth vs a year ago | — | — |
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Appili Therapeutics Inc.. Appili Therapeutics Inc. has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | Mkt cap |
|---|---|---|---|---|---|
| AAGHAmerica Great Health | Healthcare | Biotechnology | $2.1M | ||
| AGNPFAlgernon Pharmaceuticals Inc. | Healthcare | Biotechnology | $1.1M | ||
| HESGHealth Sciences Group, Inc. | Healthcare | Biotechnology | $187,094 | ||
| IBOGFUniversal Ibogaine Inc. | Healthcare | Biotechnology | $2.2M | ||
| IBXXFImagion Biosystems Limited | Healthcare | Medical - Diagnostics & Research | $2.2M | ||
| NMLSFRestart Life Sciences Corp. | Healthcare | Biotechnology | $3.5M | ||
| RGBPRegen BioPharma, Inc. | Healthcare | Biotechnology | $37,866 | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| NAMSNewAmsterdam Pharma Company N.V. | Healthcare | NASDAQ | $2.4B | ||
| NAMSWNewAmsterdam Pharma Company N.V. | Healthcare | NASDAQ | $2.3B | ||
| NAUTNautilus Biotechnology, Inc. | Healthcare | NASDAQ | $309.5M | ||
| NAVBQNavidea Biopharmaceuticals, Inc. | Healthcare | OTC | $100 | ||
| NBIONascent Biotech, Inc. | Healthcare | OTC | $51,665 | ||
| NBIXNeurocrine Biosciences, Inc. | Healthcare | NASDAQ | $16.5B | ||
| NBPNovaBridge Biosciences | Healthcare | NASDAQ | $104.1M | ||
| NBRVFNabriva Therapeutics plc | Healthcare | OTC | $646 | ||
| NBTXNanobiotix S.A. | Healthcare | NASDAQ | $1.4B | ||
| NC6.AXNanollose Limited | Healthcare | ASX | — | ||
| NCELNewcelX Ltd. | Healthcare | NASDAQ | $1.2M | ||
| NCNANuCana plc | Healthcare | NASDAQ | $5.1M | ||
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Appili Therapeutics Inc.. Coverage tracks Appili Therapeutics Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Appili Therapeutics Inc.